Last reviewed · How we verify
Placebo for estradiol gel
Placebo for estradiol gel is a Small molecule drug developed by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. It is currently FDA-approved for Control arm in clinical trials for estradiol gel formulations.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in clinical trials for estradiol gel formulations.
At a glance
| Generic name | Placebo for estradiol gel |
|---|---|
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert formulations used as controls in clinical trials to establish the efficacy of active drugs by comparison. In this case, it is a gel formulation designed to match the appearance and administration route of estradiol gel but without any hormonal activity. Any observed effects are attributable to the placebo effect or natural disease progression rather than direct pharmacological action.
Approved indications
- Control arm in clinical trials for estradiol gel formulations
Common side effects
Key clinical trials
- Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery (PHASE4)
- Brain Blood Flow Responses to Stress: Sex Differences (PHASE4)
- Menopausal HT for Women Living With HIV (HoT) (PHASE4)
- Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI (PHASE2)
- Regulation of Cortisol Metabolism and Fat Patterning (NA)
- Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy (PHASE4)
- Maintaining Suppression of Testosterone With Transdermal Estradiol Gel (PHASE2)
- Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for estradiol gel CI brief — competitive landscape report
- Placebo for estradiol gel updates RSS · CI watch RSS
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections portfolio CI